- Home
- EMN vs RVMD Comparison
EMN vs RVMD Comparison
Compare EMN & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMN
- RVMD
- Stock Information
- Founded
- EMN 1920
- RVMD 2014
- Country
- EMN United States
- RVMD United States
- Employees
- EMN N/A
- RVMD N/A
- Industry
- EMN Major Chemicals
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EMN Industrials
- RVMD Health Care
- Exchange
- EMN Nasdaq
- RVMD Nasdaq
- Market Cap
- EMN 9.2B
- RVMD 7.5B
- IPO Year
- EMN 1993
- RVMD 2020
- Fundamental
- Price
- EMN $78.33
- RVMD $37.91
- Analyst Decision
- EMN Buy
- RVMD Strong Buy
- Analyst Count
- EMN 14
- RVMD 13
- Target Price
- EMN $97.71
- RVMD $68.38
- AVG Volume (30 Days)
- EMN 1.6M
- RVMD 3.0M
- Earning Date
- EMN 07-31-2025
- RVMD 08-06-2025
- Dividend Yield
- EMN 4.24%
- RVMD N/A
- EPS Growth
- EMN 1.14
- RVMD N/A
- EPS
- EMN 7.86
- RVMD N/A
- Revenue
- EMN $9,362,000,000.00
- RVMD N/A
- Revenue This Year
- EMN N/A
- RVMD N/A
- Revenue Next Year
- EMN $3.26
- RVMD $226.82
- P/E Ratio
- EMN $9.97
- RVMD N/A
- Revenue Growth
- EMN 2.79
- RVMD N/A
- 52 Week Low
- EMN $70.90
- RVMD $29.17
- 52 Week High
- EMN $114.50
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- EMN 49.73
- RVMD 47.59
- Support Level
- EMN $76.63
- RVMD $37.72
- Resistance Level
- EMN $80.53
- RVMD $39.62
- Average True Range (ATR)
- EMN 1.85
- RVMD 1.20
- MACD
- EMN -0.02
- RVMD 0.02
- Stochastic Oscillator
- EMN 34.17
- RVMD 47.23
About EMN Eastman Chemical Company
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.